CAR-T Therapy for Autoimmune Disease in France: What's Actually Happening

What this article covers
- What This Article Covers
- France has quietly become one of the most active European sites for testing CAR-T cell therapy in severe autoimmune disease, particularly systemic lupus erythematosus (SLE) and lupus nephritis, with multiple industry-sponsored trials registered through the national health ministry's clinical trials portal and new institutional infrastructure from the country's largest public hospital network. At the same time, the field took a serious hit in September 2026 when two of the sponsors running French-registered trials paused their programs globally after patient deaths.
- The Regulatory Landscape
- No CAR-T therapy is approved anywhere in the world for an autoimmune indication; everything happening in France is investigational. That said, France's drug regulator, the Agence Nationale de Sécurité du Médicament (ANSM), maintains a standing scientific committee specifically dedicated to innovative therapy medicines (comité médicaments de thérapie innovante), which has met repeatedly through 2025 and 2026 to review cell and gene therapy dossiers, including CAR-T programs.
- What's Actually Being Tested
- The concrete trial landscape in France centers on systemic lupus and lupus nephritis, and it's more crowded than most countries can claim. France's national clinical trials registry lists several separate, actively sponsored studies: a Phase II trial of Bristol Myers Squibb's CD19-directed CAR-T (BMS-986353/CC-97540), known as BREAKFREE-SLE, for active lupus including lupus nephritis unresponsive to standard immunosuppression; a Phase I/II trial of Novartis's rapidly manufactured CD19 CAR-T, rapcabtagene autoleucel (also referred to by its development code YTB323), in severe refractory SLE; and a Phase I/II trial of Cabaletta Bio's CABA-201 in active systemic lupus.
- The Evidence Base
- , have shown that depleting CD19-positive B cells with CAR-T can produce drug-free remission in a subset of severely refractory lupus patients — often described as a "reset" of the B-cell compartment. French medical journalism, including coverage in Le Quotidien du Médecin describing CAR-T as a potential "immune reset," has tracked this excitement closely.
- Risks and a Major Red Flag
- Here the picture turns serious. In September 2026, Novartis halted its autoimmune CAR-T trials — including rapcabtagene autoleucel, one of the exact agents running in French-registered lupus studies — after three patient deaths linked to severe immune or infectious complications.
What This Article Covers
France has quietly become one of the most active European sites for testing CAR-T cell therapy in severe autoimmune disease, particularly systemic lupus erythematosus (SLE) and lupus nephritis, with multiple industry-sponsored trials registered through the national health ministry's clinical trials portal and new institutional infrastructure from the country's largest public hospital network. At the same time, the field took a serious hit in September 2026 when two of the sponsors running French-registered trials paused their programs globally after patient deaths. This article lays out what's actually on the ground in France right now: real trials, real regulatory machinery, and a real safety reckoning — not a product that patients can currently access.
The Regulatory Landscape
No CAR-T therapy is approved anywhere in the world for an autoimmune indication; everything happening in France is investigational. That said, France's drug regulator, the Agence Nationale de Sécurité du Médicament (ANSM), maintains a standing scientific committee specifically dedicated to innovative therapy medicines (comité médicaments de thérapie innovante), which has met repeatedly through 2025 and 2026 to review cell and gene therapy dossiers, including CAR-T programs. This isn't a one-off review — it's a recurring institutional function, with meeting records published on ANSM's site.
On the hospital side, France's largest public hospital network announced in February 2026 that it was rolling out what it called a large-scale action plan for innovative therapy medicines — explicitly building capacity (manufacturing coordination, apheresis logistics, specialist training) to handle the growing wave of cell and gene therapies, CAR-T included. That's a meaningful signal: it reflects an existing, functioning national apparatus for CAR-T in oncology (where CAR-T products are already approved and reimbursed through Sécurité Sociale) being consciously extended toward autoimmune applications, rather than a wish list.
What's Actually Being Tested
The concrete trial landscape in France centers on systemic lupus and lupus nephritis, and it's more crowded than most countries can claim. France's national clinical trials registry lists several separate, actively sponsored studies: a Phase II trial of Bristol Myers Squibb's CD19-directed CAR-T (BMS-986353/CC-97540), known as BREAKFREE-SLE, for active lupus including lupus nephritis unresponsive to standard immunosuppression; a Phase I/II trial of Novartis's rapidly manufactured CD19 CAR-T, rapcabtagene autoleucel (also referred to by its development code YTB323), in severe refractory SLE; and a Phase I/II trial of Cabaletta Bio's CABA-201 in active systemic lupus. These are genuine, government-registered interventional studies with French academic hospital sites involved, not wellness-clinic offerings — there is no over-the-counter or direct-to-consumer "CAR-T for autoimmune disease" product being marketed to patients in France, and the country's framework treats these strictly as clinical research under ANSM and EU Clinical Trials Regulation oversight.
France's own medical establishment has engaged publicly with the question of whether this approach belongs in autoimmune care at all: the Académie Nationale de Médecine published a dedicated scientific communication asking directly whether CAR-T cells have a place in inflammatory and autoimmune disease, reflecting active, serious institutional debate rather than hype.
The Evidence Base
The rationale driving all of this is the same one driving CAR-T-in-lupus research globally: early-phase data, mostly from Germany and the U.S., have shown that depleting CD19-positive B cells with CAR-T can produce drug-free remission in a subset of severely refractory lupus patients — often described as a "reset" of the B-cell compartment. French medical journalism, including coverage in Le Quotidien du Médecin describing CAR-T as a potential "immune reset," has tracked this excitement closely. Separately, a CD19/BCMA dual-targeted CAR-T from the biotech AbelZeta received EU fast-track designation for refractory lupus in 2026, underscoring that European regulators are treating at least some of these programs as genuinely promising enough to accelerate — real, verifiable momentum, not marketing language.
Risks and a Major Red Flag
Here the picture turns serious. In September 2026, Novartis halted its autoimmune CAR-T trials — including rapcabtagene autoleucel, one of the exact agents running in French-registered lupus studies — after three patient deaths linked to severe immune or infectious complications. Bristol Myers Squibb paused related studies in its own autoimmune CAR-T program around the same time. This was a global pause, not a France-specific one, and as of this writing other programs, including Cabaletta's CABA-201 and AbelZeta's candidate, have not been reported halted. But it's a direct, current reminder that every one of these therapies still carries the same serious toxicity profile seen in CAR-T oncology — cytokine release syndrome, neurological toxicity (ICANS), and profound immunosuppression from the lymphodepleting chemotherapy required beforehand — applied to patients with chronic, non-fatal autoimmune disease rather than cancer, which changes the risk-benefit calculus considerably.
Patient Considerations
For a French patient with severe, treatment-resistant lupus, the realistic options right now are enrollment in one of the registered academic or industry trials above — through specialist rheumatology or nephrology centers affiliated with public university hospitals — not a marketed therapy. Given the September 2026 safety pause, patients considering trial enrollment should ask specifically which sponsor and drug a given study uses, whether that program has been affected by the halt, and what monitoring protocol is in place. There is no legitimate route to CAR-T for lupus in France outside formal, regulator-approved clinical trials, and any clinic offering it as a direct-to-consumer treatment would be operating entirely outside the recognized framework.
Bottom Line
France has built real, substantive infrastructure and hosts a genuinely unusual concentration of serious CAR-T-in-lupus trials for a single country, backed by ANSM's dedicated review committee and a new institutional push across its public hospital network — but the field as a whole, in France and everywhere else, remains strictly experimental, and the September 2026 safety pause affecting two of the programs running in French trial sites is a sober, current reminder that this therapy is still a long way from being an approved, routinely available treatment for autoimmune disease.
Key Questions Answered
- Is CAR-T approved for autoimmune disease in France?
- No. CAR-T for autoimmune indications remains investigational, with access limited to formal, regulator-approved clinical trials rather than a marketed treatment.
- What changed in September 2026?
- Novartis halted autoimmune CAR-T trials after three patient deaths, and Bristol Myers Squibb paused related studies. These were global safety pauses affecting programs also registered in France.
- What should a prospective trial participant ask?
- Ask which sponsor and drug the study uses, whether the program was affected by a safety halt, and what monitoring is in place for cytokine release syndrome, neurological toxicity and profound immunosuppression.
Sources
- Comité médicaments de thérapie innovante, meeting report, Agence Nationale de Sécurité du Médicament (ANSM), 2026, https://ansm.sante.fr/uploads/2026/09/23/20260327-cr-ci-medicaments-therapie-innovante.pdf
- Médicaments de thérapie innovante: l'AP-HP met en œuvre un plan d'action d'envergure, Assistance Publique–Hôpitaux de Paris (AP-HP), 2026, https://www.aphp.fr/actualites/medicaments-de-therapie-innovante-lap-hp-met-en-oeuvre-un-plan-daction-denvergure
- Les CAR-T cells ont-elles leur place dans les pathologies inflammatoires et auto-immunes?, Académie Nationale de Médecine, 2025, https://www.academie-medecine.fr/les-car-t-cells-ont-elles-leur-place-dans-les-pathologies-inflammatoires-et-auto-immunes/
- BREAKFREE-SLE: Phase II trial of CC-97540 (BMS-986353) CAR-T cells in active SLE and lupus nephritis, French national clinical trials registry (sante.fr), 2024, https://www.sante.fr/essais-cliniques/2024-519278-37-00/
- Phase I/II trial of rapcabtagene autoleucel (YTB323) in severe refractory SLE, French national clinical trials registry (sante.fr), 2023, https://www.sante.fr/essais-cliniques/2023-510081-27-00/
- Novartis, Bristol Myers Squibb halt CAR-T cell trials due to immune events, Fierce Biotech, 2026, https://www.fiercebiotech.com/biotech/novartis-bristol-myers-squibb-halt-car-t-cell-trials-due-immune-events
- AbelZeta's CD19/BCMA-targeted CAR-T advances into European fast-track for refractory lupus, AllSci, 2026, https://allsci.com/news/expedited-pathways/abelzetas-cd19-bcma-targeted-car-t-advances-into-european-fast-track-for-refractory-lupus/
- Phase I/II trial of CABA-201 CAR-T cells in active systemic lupus erythematosus, French national clinical trials registry (sante.fr), 2023, https://www.sante.fr/essais-cliniques/2023-507613-10-01/
Related Articles
- Research & Industry
ASCO Annual Meeting 2027: What to Expect From Oncology's Biggest Stage
The world's largest clinical oncology meeting returns to Chicago in June 2027, with cell therapy, immunotherapy, and antibody-drug conjugate research expected to headline the scientific program once again.
- Research & Industry
AACR IO 2027: What to Expect From the Immuno-Oncology Conference Coming to Los Angeles
AACR IO 2027 meets in Los Angeles February 28–March 3, focusing on cancer vaccines, engineered T cells and early clinical data—not confirmed treatment advances.
- Research & Industry
2027 ASCO Genitourinary Cancers Symposium: What's Coming to San Francisco
A preview of ASCO GU 2027 in San Francisco: dates, sponsors, immunotherapy research trends and why conference findings aren't treatment approvals.